These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22800462)

  • 1. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand.
    Abdel-Aal AB; El-Naggar D; Zaman M; Batzloff M; Toth I
    J Med Chem; 2012 Aug; 55(15):6968-74. PubMed ID: 22800462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine.
    Renaudet O; BenMohamed L; Dasgupta G; Bettahi I; Dumy P
    ChemMedChem; 2008 May; 3(5):737-41. PubMed ID: 18205167
    [No Abstract]   [Full Text] [Related]  

  • 5. Robust immune responses elicited by a fully synthetic three-component vaccine.
    Ingale S; Wolfert MA; Gaekwad J; Buskas T; Boons GJ
    Nat Chem Biol; 2007 Oct; 3(10):663-7. PubMed ID: 17767155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.
    Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates.
    Lo-Man R; Vichier-Guerre S; Perraut R; Dériaud E; Huteau V; BenMohamed L; Diop OM; Livingston PO; Bay S; Leclerc C
    Cancer Res; 2004 Jul; 64(14):4987-94. PubMed ID: 15256473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli.
    Zeng W; Azzopardi K; Hocking D; Wong CY; Robevska G; Tauschek M; Robins-Browne RM; Jackson DC
    Vaccine; 2012 Jul; 30(32):4800-6. PubMed ID: 22634295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
    Wilkinson BL; Day S; Malins LR; Apostolopoulos V; Payne RJ
    Angew Chem Int Ed Engl; 2011 Feb; 50(7):1635-9. PubMed ID: 21308921
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen.
    Buskas T; Ingale S; Boons GJ
    Angew Chem Int Ed Engl; 2005 Sep; 44(37):5985-8. PubMed ID: 16108081
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
    Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
    Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTL-based cancer preventive/therapeutic vaccines for carcinomas: role of tumour-associated carbohydrate antigens.
    Franco A
    Scand J Immunol; 2005 May; 61(5):391-7. PubMed ID: 15882430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
    Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
    Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.
    Ingale S; Wolfert MA; Buskas T; Boons GJ
    Chembiochem; 2009 Feb; 10(3):455-63. PubMed ID: 19145607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
    Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
    Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.
    Yang F; Zheng XJ; Huo CX; Wang Y; Zhang Y; Ye XS
    ACS Chem Biol; 2011 Mar; 6(3):252-9. PubMed ID: 21121644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advance in carbohydrate-based cancer vaccines].
    Huo CX; Ye XS
    Yao Xue Xue Bao; 2012 Mar; 47(3):261-70. PubMed ID: 22645748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.
    Huang ZH; Shi L; Ma JW; Sun ZY; Cai H; Chen YX; Zhao YF; Li YM
    J Am Chem Soc; 2012 May; 134(21):8730-3. PubMed ID: 22587010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.